- {{heading}}
- Ab01301-1.1 Anti-EME1 [7h2/1]
- Human
- Mouse IgG1
- Purified
- In Stock
- Ab01301-1.6 Anti-EME1 [7h2/1]
- Human
- Mouse Fab fragment
- His-Tagged
- Purified
- Ships in 4-5 weeks
- Ab01301-23.0 Anti-EME1 [7h2/1]
- Human
- Rabbit IgG
- Purified
- In Stock
Recombinant monoclonal antibody to EME1. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 7h2/1.
UniProt Accession Number of Target Protein: Q96AY2
Alternative Name(s) of Target: Essential meiotic endonuclease 1; Crossover junction endonuclease EME1; MMS4 homolog; hMMS4; EC 3.1.22; EC 3.1.22.; essential meiotic endonuclease 1 homolog 1 (S. pombe); essential meiotic endonuclease 1 homolog 2; FLJ31364; homolog of yeast EME1 endonuclease; MMS4L; MMS4; SLX2 structure-specific endonuclease subunit homolog A; SLX2A; MTA31
Immunogen: The antibody was raised against His-tagged recombinant Eme1 of human origin.
Specificity: This antibody recognises human EME1. EME1 together with MUS81 create a DNA endonuclease which binds preferentially to branched DNA structures such as Holliday junctions and replication forks. It's engaged in processing of stalled or collapsed replication forks in mitosis.
Application Notes: WB: MTA31 7h2/1 antibody was used to detect EME1 in western blot analysis in the experiments assessing EME1 as a potential marker of cisplatin resistance in cancer therapy (Tomoda et al., 2009). WB: This antibody was used to detect EME1 on western blots after previous immunopurification procedure (Laguette et al., 2014). IHC: Other group conducted an immunohistochemistry experiment staining against EME1 in formalin-fixed paraffin embedded esophageal adenocarcinoma tissue samples using MTA31 7h2/1 antibody (Dwalt et al., 2014).
Antibody first published in:
Tomoda et al. Functional evidence for Eme1 as a marker of cisplatin resistance. Int J Cancer. 2009 Jun 15;124(12):2997-3001. doi: 10.1002/ijc.24268. PMID:19267403
Note on publication:
This article describes the earliest found instance of application of MTA31 7h2/1 antibody which was used to detect EME1 in western blot analysis in the experiments assessing EME1 as a potential marker of cisplatin resistance in cancer therapy.
Immunofluorescence staining of fixed RAW264.7 cells with anti-EME1 antibody 7h2/1 (Ab01301) Immunofluorescence analysis of paraformaldehyde fixed RAW264.7 cells on Shi-fix™ coverslips stained with the chimeric rabbit IgG version of 7h2/1 (Ab01301-23.0) at 10 µg/ml for 1h followed by Alexa Fluor® 488 secondary antibody (2 µg/ml), showing membrane staining. The nuclear stain is DAPI (blue) and the actin stain is phalloidin (red). Panels show from left-right, top-bottom Ab01301-23.0, DAPI, merged channels and an isotype control. The isotype control was an unknown specificity antibody (Ab00178-23.0) followed by staining with Alexa Fluor® 488 secondary antibody.
Flow cytometry using the anti-EME1 antibody 7h2/1 (Ab01301). HeLa cells were fixed using 2% PFA and stained with anti-unknown specificity antibody (Ab00178-23.0; isotype control, black line) or the rabbit IgG1 version of 7h2/1 (Ab01301-23.0, blue line) at a dilution of 1:100 for 1h at RT. After washing, the bound antibody was detected using a goat anti-rabbit IgG AlexaFluor® 488 antibody at a dilution of 1:1000 and cells analyzed using a FACSCanto flow-cytometer.